Abstract | BACKGROUND/AIMS: Loss of Smad4 function is associated with the acquisition of advanced colorectal cancer phenotypes. We investigated the role of Smad4 as a prognostic marker after curative therapy. METHODOLOGY: Four hundred and twenty nine consecutive colorectal cancers were analyzed by tissue microarray-based immunohistochemical assay. RESULTS:
Smad4 protein was expressed in 61.5% (24/39), 53.1% (77/145), 41.3% (78/189) and 34.8% (16/46) of stage I, II, III and IV cancers, respectively. Lymphovascular invasion and lymph node metastasis were strongly correlated with the loss of Smad4 expression (p<0.0001 and p=0.002, respectively). Disease-free survival did not differ between Smad4-positive and Smad4-negative cancers. In stage III disease, time to recurrence after curative therapy was shorter in the Smad4-negative than in the Smad4- positive cancers (20.1±15.1 vs. 34.6 ± 34.1 months, p=0.035). CONCLUSIONS:
|
Authors | Byung Kyu Ahn, Si-Hyong Jang, Seung Sam Paik, Kang Hong Lee |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
2011 Nov-Dec
Vol. 58
Issue 112
Pg. 1933-6
ISSN: 0172-6390 [Print] Greece |
PMID | 22024061
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- SMAD4 protein, human
- Smad4 Protein
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Colorectal Neoplasms
(pathology, therapy)
- Female
- Humans
- Immunohistochemistry
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Recurrence, Local
(chemistry)
- Neoplasm Staging
- Prognosis
- Smad4 Protein
(analysis, physiology)
- Tissue Array Analysis
|